BioSpace News Archive

The global microbial fermentation technology market size is expected to surpass around USD 54.62 billion by 2032 and is poised to grow at a CAGR of 5.84% from 2023 to 2032.

Trethera Corporation announced that it was awarded a $0.6M Small Business Technology Transfer grant from the National Institute for Allergy and Infectious Diseases.

AIM ImmunoTech Inc. announced the publication of pre-clinical data that suggests Ampligen has the potential to act directly on tumor cells to reduce tumor cell growth in pancreatic cancer patients with sufficient tumor levels of TLR-3, suggesting a potential biomarker to identify patients who may respond to Ampligen.

On its 25th anniversary, the high-tech pharmaceutical company dedicated to innovation has received its first Marketing Authorization Approval in China for AUXITON®, the oral finished dosage form of Dydrogesterone, from China’s Health Authority, the NMPA.

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, acknowledged receipt of a letter from NexPoint Asset Management, L.P., together with its affiliates.

Magdalena Zernicka-Goetz, PhD, was announced as the recipient of the 2023 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes.

The U.S. Food and Drug Administration is providing an update on its proposal to create a unified Human Foods Program, which includes a new model for the Office of Regulatory Affairs.

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, reports that after nearly a year of research, the UCLA team is ready to begin integrating their combined work into a complete vaccine construct for next phase testing and optimization.

Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces Ascendia’s patented EmulSol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval from the Food & Drug Administration (FDA).

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced top-line, two-year (96 weeks) data for aflibercept 8 mg from the pivotal PHOTON trial in patients with diabetic macular edema (DME).